NewsBenzinga報告された土曜日、GSKのジェンペリ単剤療法は、概ね一貫した安全性を示し、重篤な有害反応は20％、中止は3％で、第II相AZUR-1 MSI-H/dMMR直腸がん試験では76％の完全奏効を示した 報告された土曜日、GSKのジェンペリ単剤療法は、概ね一貫した安全性を示し、重篤な有害反応は20％、中止は3％で、第II相AZUR-1 MSI-H/dMMR直腸がん試験では76％の完全奏効を示した Benzinga 2026.10.26 07:32 (GMT+0) Open on Benzinga Other news BMO Capital Initiates Coverage On FirstEnergy with Outperform Rating, Announces Price Target of $50 Why Surgery Partners Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket Support for semiconductor stocks could be as much as 15% lower than current levels, says Morgan Stanley Weekly Market Pulse: Where The Puck Will Be Amcor’s Quarterly Earnings Preview: What You Need to Know Apple's Design Team Didn't Want Touchscreen Macs, But Tim Cook and John Ternus Had Other Ideas: Report
Support for semiconductor stocks could be as much as 15% lower than current levels, says Morgan Stanley
Apple's Design Team Didn't Want Touchscreen Macs, But Tim Cook and John Ternus Had Other Ideas: Report
